LPOXY Raises $28 Million Series A to Fund STOP-Cdiff Trial
September 3, 2025
LPOXY Therapeutics, Inc., a clinical-stage biopharmaceutical company, is developing a new way to prevent Clostridioides difficile infections (C. diff) that doesn’t rely on antibiotics. The